Allergan settles with Zydus and Cadila over Delzicol: 4 things to know

Dublin, Ireland-based Allergan Pharmaceuticals settled litigation over its Delzicol prescription used to treat ulcerative colitis.

Advertisement

Here’s what you should know.

1. Allegan settled with Pennington, N.J.-based Zydus Pharmaceuticals and Ahmedabad, India-based Cadila Healthcare.

2. If approved by the FDA, Zydus and Cadila could market generic versions of Delzicol in the United States beginning March 1, 2020.

3. No details regarding the statement were available.

4. Allergan’s stocks opened at $190.40 on Dec. 2, 2016 and closed at $189.71. At noon on Dec. 5, 2016 the stock was up to $190.24.

More articles on gastroenterology/endoscopy news:
AGA Patient INFO Center integrates with gMed: 3 notes
Allergan’s GI business grows by 8.2% in Q3 & more — 3 GI company key notes
Valeant, Takeda deal crumbles; Valeant to invest in Salix: 6 things to know 

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Birmingham (Ala.) Gastroenterology has opened a clinic in Jasper, Ala., expanding access to digestive health services in the region, the…

  • Premier Health Partners has acquired Dayton, Ohio-based Digestive Specialists, according to a notice posted on the website of law firm…

Advertisement

Comments are closed.